Scarica l'app Stockscreener
13.64
5.27%
-0.7714
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.41
Aprire:
$14.41
Volume 24 ore:
365.00K
Relative Volume:
0.42
Capitalizzazione di mercato:
$1.30B
Reddito:
-
Utile/perdita netta:
$-249.31M
Rapporto P/E:
-4.1204
EPS:
-3.31
Flusso di cassa netto:
$-209.70M
1 W Prestazione:
-3.26%
1M Prestazione:
-19.61%
6M Prestazione:
-37.76%
1 anno Prestazione:
-41.72%
Intervallo 1D:
$13.60
$14.59
Intervallo di 1 settimana:
$13.60
$14.68
Portata 52W:
$12.62
$32.52
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Nome
Rocket Pharmaceuticals Inc
Settore
Industria
Telefono
646-440-9100
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Confronta RCKT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
13.65 | 1.30B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.88 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.83 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.19 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.42 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Iniziato | Morgan Stanley | Overweight |
| 2022-11-08 | Iniziato | Canaccord Genuity | Buy |
| 2022-11-01 | Iniziato | BTIG Research | Buy |
| 2022-07-08 | Iniziato | Raymond James | Outperform |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2021-02-18 | Iniziato | Needham | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Iniziato | JP Morgan | Overweight |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2019-11-06 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-26 | Iniziato | Piper Jaffray | Overweight |
| 2019-04-23 | Iniziato | Robert W. Baird | Outperform |
| 2019-03-15 | Iniziato | BofA/Merrill | Buy |
| 2019-02-05 | Iniziato | Oppenheimer | Outperform |
| 2018-09-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-07-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha
RCKT (Rocket Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 30, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
RCKT (Rocket Pharmaceuticals) PE Ratio without NRI : At Loss (As of Nov. 29, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Nov. 28, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) 50-Day SMA : $16.76 (As of Nov. 28, 2024) - GuruFocus.com
Acuta Capital Partners LLC Sells 60,370 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
3 Small-Cap Stocks That Are Ready to Rocket Higher - sharewise
Fiverr International Ltd (FVRR-N) QuotePress Release - The Globe and Mail
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference - BioSpace
Rocket Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock eyes $1B+ peak sales - Investing.com
(RCKT) Long Term Investment Analysis - Stock Traders Daily
Westfield Capital Management Co. LP Acquires 165,911 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.3%Time to Buy? - MarketBeat
Leerink Partnrs Has Strong Outlook for RCKT FY2025 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - MarketBeat
Rocket Pharmaceuticals' (RCKT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Buy Rating from Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data - StreetInsider.com
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):